Avatrombopag hydrochloride T40654
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
200 mg | 570403-17-7 | 面议 | 询底价 |
100 mg | 570403-17-7 | 面议 | 询底价 |
10 mg | 570403-17-7 | ¥4,160.00 | 询底价 |
50 mg | 570403-17-7 | ¥12,400.00 | 询底价 |
1 mL | 570403-17-7 | ¥4,390.00 | 询底价 |
5 mg | 570403-17-7 | ¥2,890.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Avatrombopag hydrochloride
描述: Avatrombopag hydrochloride (AKR-501) is an orally active, nonpeptide agonist of the thrombopoietin (TPO) receptor with an EC 50 of 3.3 nM. It effectively mimics the biological activities of TPO, stimulating platelet production by activating the intracellular signaling system and facilitating the generation of platelets and megakaryocytes from hemopoietic precursor cells. Additionally, Avatrombopag hydrochloride serves as a substrate for cytochrome P450 (CYP) 2C9 and CYP3A.
体外活性: Avatrombopag (E5501; AKR-501) hydrochloride specifically targets the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as recombinant human TPO (rhTPO) did. Avatrombopag hydrochloride is showed to have effect in humans and chimpanzees only[1]. Avatrombopag hydrochloride (0-100 nM) supports the proliferation of TPO receptor expressing Ba/F3 cell in a concentration-dependent fashion. Avatrombopag hydrochloride (0-3 μM) induces tyrosine phosphorylation of STAT3 and STAT5, and threonine phosphorylation of ERK in the cells, as did rhTPO[1]. Avatrombopag hydrochloride promotes megakaryocyte colony formation from human CB CD34 + cells in a concentration-dependent fashion. The EC 50 is 25 nM for Avatrombopag hydrochloride and the maximum activity of Avatrombopag hydrochloride is similar to that of rhTPO[1].
体内活性: Avatrombopag hydrochloride (0.3-3 mg/kg; p.o.; daily for 14 days) increases the number of human platelets in NOD/SCID mice transplanted with human FL CD34 + cells[1]. Animal Model: NOD/SCID mice (transplanted with human FL CD34+cells)[1]Dosage: 0.3, 1, and 3?mg/kg Administration: P.o.; daily for 14 days Result: Dose-dependently increased the number of human platelets, resulting in approximately a 2.7‐fold increase at 1 mg/kg/d and a 3.0-fold increase at 3 mg/kg/d on day 14 after the start of administration.
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
关键字: AKR 501 Hydrochloride | Avatrombopag hydrochloride | AKR-501 Hydrochloride | AKR501 Hydrochloride | Avatrombopag Hydrochloride
Avatrombopag hydrochloride T40654信息由TargetMol中国为您提供,如您想了解更多关于Avatrombopag hydrochloride T40654报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途